Building contracts divided into two parts deliveries are 1) three pieces of therapeutic separators intended for routine diagnosis of extracorporeal photochemotherapy
and preparation of mononuclear cells to anti-tumor vaccines2) 1 piece separator for donor interventions - the separation of platelets deleucotized in line at a centrifugal separation procedure.
Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy.
Extracorporeal photochemotherapy for the treatment of graft-versus-host disease.
Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease.
Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation.
Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study.
The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease.
Theralux(TM) comprises several different clinical programs, including Theralux(TM)-ECP, a program to treat autoimmune diseases refractory to standard therapies through the process of extracorporeal photochemotherapy
(ECP) and Theralux(TM)-GvHD, a program for leukemia and lymphoma patients to facilitate mismatched blood stem cell transplants by providing patients with donor T cells necessary to fight infections pretreated with Theralux(TM) to reduce their ability to cause graft-versus-host disease (GvHD) without reducing their ability to fight infections and the leukemia.
Building contracts divided into two parts deliveries are:1) three pieces of therapeutic separators intended for routine diagnosis for extracorporeal photochemotherapy
and preparation of mononuclear cells in a cancer vaccine;2) 1 piece separator for donor interventions - the separation of platelets deleucotized in line at a centrifugal separation procedure.
3) ECP for treatment of autoimmune diseases: the treatment of blood from an autoimmune or chronic GvHD patient to remove the offending immune cells and alter the immune response in the patient; this process is known as extracorporeal photochemotherapy
Investigators found that Targretin capsule therapy reliably induced rapid responses in these erythrodemic patients who had been refractory to interferon, extracorporeal photochemotherapy
, electron beam radiotherapy, photochemotherapy with ultraviolet-A, topical chemotherapy, systemic chemotherapy, and combinations of these therapies.